These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 35871310)

  • 1. SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.
    Terpos E; Fotiou D; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Gavriatopoulou M; Malandrakis P; Iconomidou VA; Kastritis E; Trougakos IP; Dimopoulos MA
    Am J Hematol; 2022 Oct; 97(10):1300-1308. PubMed ID: 35871310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
    PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
    Terpos E; Gavriatopoulou M; Fotiou D; Giatra C; Asimakopoulos I; Dimou M; Sklirou AD; Ntanasis-Stathopoulos I; Darmani I; Briasoulis A; Kastritis E; Angelopoulou M; Baltadakis I; Panayiotidis P; Trougakos IP; Vassilakopoulos TP; Pagoni M; Dimopoulos MA
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
    Campanella A; Capasso A; Heltai S; Taccetti C; Albi E; Herishanu Y; Haggenburg S; Chatzikonstantinou T; Doubek M; Kättström M; Giannopoulos K; Simkovic M; Moreno C; Massaia M; Bumbea H; Alshemmari S; Ranghetti P; Perotta E; Martini F; Sant'Antonio E; Colia M; Combi C; Levi S; Kater AP; Hazenberg M; Nijhof IS; Hofsink Q; Demosthenous C; Kotaskova J; Zaleska J; Vrbacky F; Raya AM; Bisogno D; Tripoli IE; Popov VM; Roman V; Stavroyianni N; Karypidou M; Scarano E; Locatelli M; Frenquelli M; Scarfò L; Stamatopoulos K; Ghia P
    Am J Hematol; 2024 Apr; 99(4):745-750. PubMed ID: 38264829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
    Tomasulo E; Paul S; Mu R; Tian X; Chen J; Pleyer C; Wiestner A; Sun C
    Leuk Lymphoma; 2023 Dec; 64(14):2306-2315. PubMed ID: 37732614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals.
    Terpos E; Karalis V; Ntanasis-Stathopoulos I; Apostolakou F; Gumeni S; Gavriatopoulou M; Papadopoulos D; Malandrakis P; Papanagnou ED; Korompoki E; Kastritis E; Papassotiriou I; Trougakos IP; Dimopoulos MA
    Hemasphere; 2022 Jan; 6(1):e677. PubMed ID: 34938959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Spike and Neutralizing Antibodies after Two Doses of COVID-19 Sinopharm/BIBP Vaccine.
    Omran EA; El Naggar RE; Ezz Elarab LA; Hashish MH; El-Barrawy MA; Abdelwahab IA; Fekry MM
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
    Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
    Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2.
    Fylaktou A; Stai S; Kasimatis E; Xochelli A; Nikolaidou V; Papadopoulou A; Myserlis G; Lioulios G; Asouchidou D; Giannaki M; Yannaki E; Tsoulfas G; Papagianni A; Stangou M
    Vaccines (Basel); 2023 Oct; 11(11):. PubMed ID: 38006002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan.
    Marumo Y; Yoshida T; Furukawa Y; Ina K; Kamiya A; Kataoka T; Kayukawa S
    Clin Exp Vaccine Res; 2023 Oct; 12(4):319-327. PubMed ID: 38025915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
    Kontandreopoulou CN; Solomou EE; Kolorizos E; Diamantopoulos PT
    Ann Hematol; 2024 Jul; ():. PubMed ID: 39008060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines.
    Padmanabhan P; Desikan R; Dixit NM
    Nat Comput Sci; 2022 Feb; 2(2):123-131. PubMed ID: 38177523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
    Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Schmitt AM; Tippu Z; Farag S; Rogiers A; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Barber T; Emslie-Henry A; Caulfield-Lynch N; Byrne F; Shum B; Gerard CL; Deng D; Kjaer S; Song OR; Queval C; Kavanagh C; Wall EC; Carr EJ; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Shea RL; Gardner G; Murray D; Popat S; Yousaf N; Jhanji S; Van As N; Young K; Furness AJS; Pickering L; Beale R; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Howell M; Nicholson E; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
    Cancer Cell; 2022 Apr; 40(4):438. PubMed ID: 35413273
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).
    Terpos E; Musto P; Engelhardt M; Delforge M; Cook G; Gay F; van de Donk NWCJ; Ntanasis-Stathopoulos I; Vangsted AJ; Driessen C; Schjesvold F; Cerchione C; Zweegman S; Hajek R; Moreau P; Einsele H; San-Miguel J; Boccadoro M; Dimopoulos MA; Sonneveld P; Ludwig H
    Leukemia; 2023 Jun; 37(6):1175-1185. PubMed ID: 37142661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination.
    Rosati M; Terpos E; Bear J; Burns R; Devasundaram S; Ntanasis-Stathopoulos I; Gavriatopoulou M; Kastritis E; Dimopoulos MA; Pavlakis GN; Felber BK
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.
    Liatsou E; Ntanasis-Stathopoulos I; Lykos S; Ntanasis-Stathopoulos A; Gavriatopoulou M; Psaltopoulou T; Sergentanis TN; Terpos E
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.
    Terpos E; Branagan AR; García-Sanz R; Trotman J; Greenberger LM; Stephens DM; Morel P; Kimby E; Frustaci AM; Hatjiharissi E; San-Miguel J; Dimopoulos MA; Treon SP; Leblond V
    Semin Hematol; 2023 Mar; 60(2):107-112. PubMed ID: 37099029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials.
    Filippatos C; Ntanasis-Stathopoulos I; Sekeri K; Ntanasis-Stathopoulos A; Gavriatopoulou M; Psaltopoulou T; Dounias G; Sergentanis TN; Terpos E
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992474
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.